Early Response Impact on Signal Detection in Placebo Study

How can early symptom improvements in depression influence the outcomes of clinical trials?

Discover the findings of a study that explored the relationship between early treatment response and signal detection in a placebo-controlled trial for major depressive disorder (MDD).

Learn how early changes in depressive symptoms, measured by the QIDS-SR 16 scale, impacted the effectiveness of a combination treatment compared to buspirone and placebo.

This analysis sheds light on the complexities of placebo response, trial design challenges, and the importance of investigating mediating factors for improved outcomes in MDD research.

This article originally appeared in Personalized Medicine in Psychiatry by authors Steven D. Targum and Christopher J. Catania.